Teladoc Health and Dexcom Offers CGM-Powered Insight for T2D

Shots:

  • The companies reported that joint Livongo for diabetes and dexcom members will now receive CGM-powered insights that enables members to easily visualize their health information and understand how lifestyle decisions affect their blood glucose levels
  • In Oct’2020, Teldoc merges with Livongo while in Jan’2020 Dexcom collaborated with Livongo to integrate Dexcom’s G6 CGM system into Livongo’s applied health signals platform
  • Both the companies will launch a pilot demonstrating the impact of CGM-powered insights for people with T2D, with a broader launch across 2021

Click here ­to­ read full press release/ article | Ref: Teladoc Health | Image: Teladoc Health

The post Teladoc Health and Dexcom Offers CGM-Powered Insight for T2D first appeared on PharmaShots.

Sanofi to Acquire Kiadis for ~$358M

Shots:

  • Sanofi to acquire all outstanding shares of Kiadis for $6.34/ share, representing an equity value of $358.76M. The offer price represents a premium of 272% over the closing price on Oct 30, 2020, a premium of ~247% over the 30 trading days VWAP and a premium of ~200% over the 90 trading days VWAP
  • The transaction is expected to be completed in H1’21. The addition of Kiadis’ NK cell platform and pipeline of cell-based cancer immune-therapeutics & infectious disease therapies complements Sanofi’s existing therapeutic expertise
  • In July’2020, Sanofi licensed Kiadis’ pre-clinical K-NK004 program for MM. Sanofi’s infrastructure and capabilities will be leveraged to advance the development of Kiadis’ pipeline

Click here to­ read the full press release/ article | Ref: Sanofi | Image: Kiadis

The post Sanofi to Acquire Kiadis for ~8M first appeared on PharmaShots.